Moderna, Merck mRNA cancer vaccine meets key endpoints in melanoma trial, cutting recurrence or death risk 42%
The detailed Phase 2b data for the individualized neoantigen therapy support a treatment that pairs mRNA with Keytruda, a closely watched test of mRNA beyond in
inkl · +14 outlets
Novo Nordisk's CagriSema shows 25% weight loss, lifting obesity drug outlook
The next-generation combination readout sets up Novo's answer to Lilly's retatrutide and supports obesity-focused ETF interest.
The Globe and Mail · +11 outlets
Novo Nordisk halves US price of weight-loss drug, cutting Wegovy costs
The price cut intensifies competition with Eli Lilly and reflects pressure from compounded alternatives and payer scrutiny.
BusinessWorld Online · +14 outlets
AstraZeneca's Ultomiris wins FDA accelerated approval for primary IgA nephropathy in adults
The nod extends the complement inhibitor franchise into a rare kidney disease with limited approved options.
Pharmaceutical Executive · +14 outlets
Eli Lilly to build $3.5 billion Pennsylvania weight-loss drug plant
The manufacturing investment is aimed at easing capacity constraints for Lilly's incretin franchise amid surging demand.
BusinessWorld Online · +14 outlets
Pfizer to halt development of closely watched weight-loss drug
The decision removes one of the larger pharma entrants from the oral obesity race and raises questions about its metabolic pipeline strategy.
BusinessWorld Online · +12 outlets
GSK wins FDA approval for Hibsago in chronic hepatitis B
The approval targets a functional cure in a large chronic infection population that has seen little therapeutic innovation.
Mugglehead Investment Magazine · +14 outlets
Biohaven shares post biggest one-day gain in four years as FDA accepts Vyglxia resubmission
The regulatory acceptance revives a closely watched neuropsychiatric asset after a prior rejection, re-rating the stock.
TradingView · +8 outlets
ICER and West Health report finds median US drug launch prices hit $257,000
The pricing analysis underscores persistent affordability concerns despite policy efforts to lower US drug costs.
Pharmaceutical Executive · +7 outlets
Aardvark Therapeutics shares surge after FDA lifts clinical hold on ARD-101 for Prader-Willi syndrome
The lifted hold clears the company to advance an oral gut-hormone candidate targeting hyperphagia in the rare genetic disorder.
Investing.com · +3 outlets
Arbutus Biopharma says FDA lifts clinical hold on oral hepatitis B drug AB-101
Resumption of the trial restores a key pipeline program for a company focused on functional cure of chronic hepatitis B.
Mugglehead Investment Magazine · +5 outlets
Compounded GLP-1 drugs recalled over unapproved weight-loss alternatives concerns
The recall adds to scrutiny of copycat semaglutide and tirzepatide products sold outside the branded supply chain.
The Boston Globe · +2 outlets
GSK's Jemperli wins FDA approval, expanding AnaptysBio royalty potential
The checkpoint inhibitor approval broadens an endometrial cancer franchise that carries royalty obligations to AnaptysBio.
Simply Wall Street · +3 outlets
Mineralys Therapeutics Phase 3 data show lorundrostat lowers blood pressure and albuminuria in CKD
The data support a hypertension drug candidate targeting an aldosterone synthase mechanism in chronic kidney disease.
Quiver Quantitative · +9 outlets
Hanmi launches Korea's first domestically developed GLP-1 obesity drug
The launch marks a domestic entrant into a Korean obesity market dominated by imported GLP-1 therapies.
Chosunbiz · +13 outlets
Edwards Lifesciences wins FDA approval for PASCAL tricuspid repair system
The approval makes Edwards the only US company offering repair or replacement therapies for both mitral and tricuspid valves.
Mugglehead Investment Magazine · +8 outlets
AbbVie's skin disease drug reduces lesions in trial, company eyes weight-loss combination
The readout supports AbbVie's immunology franchise and signals ambitions to combine assets with obesity therapies.
Reuters · +1 outlets
AstraZeneca's lung cancer drug now available in US after 46% trial response rate
The US launch extends AstraZeneca's oncology portfolio into a new lung cancer indication.
Stock Titan